BioCentury on BioBusiness,
Table: Merck Serono deals
Back to the parent article
Monday, March 19, 2012
Since the beginning of 2011, Merck Serono S.A. has
done at least eight deals to either in-license or generate candidates in
autoimmune, inflammation, cancer and neurodegenerative diseases for its
pipeline. During 2007-10, the pharma had done four or five deals a year. Source:
BCIQ: BioCentury Online Intelligence
description (prod status at time of deal)
Pharmaceuticals Inc. (NASDAQ:THLD)
and commercialize TH-302, a hypoxia-activated cytotoxic2-nitroimidazole
prodrug of the DNA alkylator bromoisophosphoramide mustard (Br-IPM); in Ph
III to treat soft tissue sarcoma (STS) and Ph II for advanced pancreatic
up front; up to $525M in milestones; tiered, double-digit royalties; Threshold
has option to co-commercialize in U.S. and receive up to 50% of profits
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2014 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]